Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Murthy

Showing results (831-840 of 873) with videos related to

Pageof 88
Sort By:
Journal of Virology|June 14, 2003
Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag geneDanilo R Casimiro, Aimin Tang, Ling Chen, et al.
Journal of the Canadian Association of Gastroenterology|September 7, 2023
The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBDStephanie Coward, Eric I Benchimol, M Ellen Kuenzig, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
JAMA Oncology|December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialNancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Nature Cancer|March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study resultsRashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Gastroenterology|April 19, 2026
Pre-Crohn's Disease Stool from Discordant Siblings Promotes the Development of Colitis in Germ-Free MiceCong Phi Dang, Alice Chen-Liaw, Mingyue Xue, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis CanadaEric I Benchimol, Charles N Bernstein, Alain Bitton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Journal of the Canadian Association of Gastroenterology|November 10, 2021
Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation StrategyGilaad G Kaplan, Joseph W Windsor, Janet Crain, et al.
Pageof 88

Showing results (831-840 of 873) with videos related to

Sort By:
Pageof 88
Journal of Virology|June 14, 2003
Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag geneDanilo R Casimiro, Aimin Tang, Ling Chen, et al.
Journal of the Canadian Association of Gastroenterology|September 7, 2023
The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBDStephanie Coward, Eric I Benchimol, M Ellen Kuenzig, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
JAMA Oncology|December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialNancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Nature Cancer|March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study resultsRashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Gastroenterology|April 19, 2026
Pre-Crohn's Disease Stool from Discordant Siblings Promotes the Development of Colitis in Germ-Free MiceCong Phi Dang, Alice Chen-Liaw, Mingyue Xue, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis CanadaEric I Benchimol, Charles N Bernstein, Alain Bitton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Journal of the Canadian Association of Gastroenterology|November 10, 2021
Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation StrategyGilaad G Kaplan, Joseph W Windsor, Janet Crain, et al.
Pageof 88